HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Therapeutic efficacy of decreased nitrite production by bezafibrate in patients with primary biliary cirrhosis.

AbstractBACKGROUND:
The therapeutic efficacy of bezafibrate, a hypolipidemic drug, has been shown in patients with primary biliary cirrhosis (PBC) in some pilot studies; however, little is known regarding the mechanism of action of bezafibrate in PBC. This study was conducted to evaluate the therapeutic efficacy, as well as to gain insight about the possible mechanism of action, of bezafibrate in PBC.
METHODS:
Sixteen patients with PBC were administered with bezafibrate (400 mg/day) either with (n = 10) or without ursodeoxycholic acid (UDCA; n = 6). The peripheral blood of these patients was collected before and at different times after therapy commencement, and antigen-presenting dendritic cells (DCs) were then cultured. The DCs were enriched and cultured with Staphylococcus aureus Cowan strain-1 for 48 h to evaluate their capacity to produce nitrite.
RESULTS:
One month after the start of bezafibrate therapy, the serum levels of alkaline phosphatase (P = 0.0005), gamma-glutamyl transpeptidase (P = 0.0006), total cholesterol (P = 0.0072), and immunoglobulin M (P = 0.0281) were decreased significantly compared to those before patients started bezafibrate therapy. The levels of nitrite produced by DCs decreased in all patients with PBC within 1 month of commencement of bezafibrate therapy. Moreover, decreased nitrite production by DCs was also seen when nitrite production was evaluated 1 year after the start of bezafibrate therapy.
CONCLUSIONS:
This study reconfirms the therapeutic efficacy of bezafibrate in patients with PBC, including those with UDCA-resistant PBC. Downregulation of nitrite production by DCs may have some relationship with the therapeutic efficacy of bezafibrate; however, further study will be needed to clarify whether or not the antiinflammatory activity of bezafibrate is mediated through nitrite production.
AuthorsSk Md Fazle Akbar, Shinya Furukawa, Seiji Nakanishi, Masanori Abe, Norio Horiike, Morikazu Onji
JournalJournal of gastroenterology (J Gastroenterol) Vol. 40 Issue 2 Pg. 157-63 (Feb 2005) ISSN: 0944-1174 [Print] Japan
PMID15770399 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Hypolipidemic Agents
  • Nitrites
  • Bezafibrate
Topics
  • Adult
  • Bezafibrate (pharmacology, therapeutic use)
  • Female
  • Humans
  • Hypolipidemic Agents (pharmacology, therapeutic use)
  • Liver Cirrhosis, Biliary (drug therapy, physiopathology)
  • Liver Function Tests
  • Middle Aged
  • Nitrites (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: